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Abstract: Herpes keratitis is the most common infectious cause of blindness in the developed world. It may be treated 
by acyclovir (ACV), however this antiviral drug is poorly soluble with low ocular bioavailability requiring high and 
frequent dosing. Nanostructured lipid carriers (NLCs) were investigated to improve the ocular bioavailability of ACV by 
enhancing corneal penetration as well as prolonging the exposure of infected cells to the antiviral agent. NLCs were 
fabricated by the hot microemulsion technique and coated with 0.5% w/v chitosan. Cell uptake studies, ex vivo tolerance 
and cell uptake efficacy as well as in vivo corneal permeation of the developed lipid based formulations were investigated. NLCs were 
capable of increasing the cell uptake of encapsulated fluorescein and ACV as examined by fluorescence microscopy and high performance 
liquid chromatography (HPLC) respectively. When entrapped in NLCs, the antiviral efficacy of ACV was increased by 3.5 fold after 24 hrs 
of exposure. The in vivo corneal permeation of the formulation was studied on Albino rabbits with NLCs capable of increasing the corneal 
bioavailability by 4.5 fold when compared to a commercially available ACV ophthalmic ointment. In conclusion, NLCs enhanced the ocular 
bioavailability and antiviral properties of ACV through cell internalization, sustained release, and increased corneal permeation.  
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1. INTRODUCTION 
 Herpes simplex virus (HSV) is a large complex 
DNA virus from the family herpesviridae, which is 
ubiquitous and contagious. Herpes simplex type 1 (HSV-1) 
and 2 (HSV-2) infections are common viral infections seen 
in patients of every age and ethnicity and can affect almost 
any organ at any time of the year. A primary ocular infection 
is often followed by a secondary infection due to the 
establishment of HSV-1 latency in neurons of the trigeminal 
ganglion [1]. Once reactivated, HSV-1 can infect the 
posterior eye via axonal transport and spread to the anterior 
eye resulting in corneal disease, stromal scarring and 
blindness. 
Acyclovir (ACV) is a potent antiviral agent against HSV-1 
but due to its poor bioavailability, frequent administration of 
high doses is often necessary to attain the minimum effective 
concentration. Five daily administrations are required when 
given orally as 200-400 mg tablets while the IV dose is 
usually 5-10 mg/kg 8 hourly for one week. Topically, a 5% 
ointment is typically applied on the affected area up to six 
times a day for one week, often resulting in poor patient 
compliance.  
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Therefore, there is a need to develop a sustained release 
ocular formulation capable of improving ocular 
bioavailability as well as reducing the required dose and 
frequency of administration. We have previously reported 
that Solid Lipid Nanoparticles (SLNs) and their latest 
structural modified derivatives, Nanostructured Lipid 
Carriers (NLCs), are capable of providing sustained ACV 
release [2]. The resultant particles had satisfactory 
pharmaceutical characteristics but were negatively charged 
and exhibited a rather fast drug release profile.  As corneal 
epithelial cells bear negative charges, conversion of NLCs to 
positively charged particles is expected to significantly 
increase the precorneal residence time of the formulation and 
subsequently increase corneal penetration [3]. This approach 
has also been used for other biomedical applications such as 
transdermal drug delivery as well as encapsulation of DNA 
and other bioactive substances that require ionic interactions 
[4-8]. Moreover, in theory, coating of nanoparticles with a 
natural polymer should further reduce the drug release rate. 
Chitosan has previously been used to prepare vesicular drug 
delivery systems, as permeation enhancer and as coating 
polymer in the preparation of surface modified ophthalmic 
formulations. Several ocular drug delivery systems such as 
microspheres, colloids and nanoparticles have been 
developed to deliver a wide range of drugs and bioactives [9-
14], with the second generation of colloidal drug carriers 
coated with bioadhesive polymers to improve the transport 
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of the encapsulated drugs [14]. Chitosan coated 
nanoparticles have been found to be more effective in terms 
of the amount of the drug permeated through the cornea 
compared to uncoated particles [15]. As well as being a pH-
responsive, the amine groups of this polymer can interact 
with the negatively charged sialic acid groups of the mucin 
present on the corneal surface, thus resulting in prolonged 
residence time [16].  Despite the versatility of 
nanoparticulate drug delivery systems coated with chitosan, 
only those with an optimal release rate are suitable for 
ophthalmic use since carrier contact time with the absorption 
site (corneal epithelium) is short and limited [17]. The 
emergence of newer preparation techniques such as self-
assembly methods for lipid nanoparticle preparation, which 
for instance requires low energy consumption and is suitable 
for industrial applications, make lipid nanoparticles a 
potential and commercially viable drug delivery platform 
[18-20]. The aim of this study was to coat ACV loaded 
NLCs with chitosan in order to obtain sustained drug release, 
increase the corneal residence time and enhance the corneal 
permeability of ACV.  
2. MATERIALS AND METHOD (FOR RESEARCH 
ARTICLES ONLY) 
2.1. Materials 
ACV powder (Jai Radhe Sales, India), Lauroglycol® 90, 
Compritol® 888 ATO, low molecular weight chitosan (LCH)  
and Tween® 40 (Sigma, Germany) were used in the 
preparation of NLCs. Sodium fluorescein (Sigma, Germany), 
gastric mucin (Hangzhou Dayangchem Co. Limited, China), 
CoverWellTM perfusion chambers (20 mm×2.5 mm) were 
purchased from Sigma-Aldrich (New Zealand) and a 
fluorescence microscope (Axioplan2, Zeiss, Germany) was 
used for the measurement of precorneal residence time. 
Zovirax ophthalmic antiviral ointment (GlaxoSmithKline, 
New Zealand) was used as a control in the in vivo release 
study. Petroleum jelly (Multichem, New Zealand) was used 
to dilute the Zovirax ointment. Size 26G ½ (0.45 x 13mm) 
and 21G 1 ½ TW (0.8mm x 38mm) needles (BD 
PrecisionGlideTM Needles, Singapore) were used to collect 
ocular fluid samples. Guanosine (Sigma, Germany) was used 
as high performance liquid chromatography (HPLC) internal 
standard. Phosphate buffer solution (PBS) and all other 
chemical used were of analytical grade.  
2.2. HPLC method of detection: 
HPLC was used to analyse ACV concentrations based on a 
previously published method [21]. An Agilent 1200 series 
(Agilent Technologies, Germany) equipped with a 
quaternary pump, a vacuum solvent microdegasser, an 
autosampler with 100-well tray and an online diode array 
detector were employed [22]. The output signal was 
monitored and processed using ChemStation software 
(Agilent Technologies, Germany). The mobile phase 
comprising of acetonitrile and 0.05 M ammonium acetate 
with a pH of 5.4 using acetic acid (3:97, v/v) was pumped 
through a cosmosil packed column (5C18-AR, 4.6×250 mm, 
Nacalai Tesque, Japan) at a rate of 1 mL/min at 25 oC with a 
detection wavelength of 254 nm. Calibration curves were 
linear over the concentration range of the study (r2=0.999).  
2.3. Preparation of NLCs 
NLCs were prepared according to the previously published 
hot microemulsion technique [2]. Briefly, ACV (7% w/w) 
was dispersed in the liquid lipid (Lauroglycol® 90) now 
before adding the solid lipid (Compritol® 888 ATO) (58% 
w/w). The solid lipid was then melted at 80 oC which was 10 
oC above its melting point. The aqueous phase containing the 
surfactant (Tween® 40) was heated to the same temperature. 
A primary o/w emulsion was formed by homogenisation (3 
min at 20,500 rpm using an Ultra-Turrax T-10, IKA, 
Germany) of the lipid melt in the aqueous phase. The hot 
emulsion was then cooled in an ice bath and homogenisation 
was continued for 7 min at 20,500 rpm using an Ultra-Turrax 
T-10 until NLCs were formed. Particles were separated by 
ultracentrifugation at 30,000 rpm for 30 min and washed 
with cold water to remove excess surfactants. The purified 
particles were dispersed in 5 mL of cold Milli Q water and 
were deep-frozen overnight. Subsequently NLCs were 
lyophilised at -20 oC at below 0.133 mBar for 24 hrs to 
obtain a dry powder (Labconco-7806020, USA). NLCs were 
coated by dispersing them in different concentrations of 
chitosan solutions (0.1, 0.25, 0.5 and 1% w/v of LCH) at a 
1:5 (w/v) ratio and stirring at 600 rpm for 20 min at ambient 
temperature.  
The fluorescein containing NLCs were prepared by replacing 
the drug with sodium fluorescein and the whole procedure 
was carried out in a dark room to avoid photobleaching. The 
concentration of fluorescein in NLCs was 0.01 mg mL-1.  
2.4. Characterisation of NLCs 
The average particle size and zeta potential of nanoparticles 
were measured immediately after preparation by the light 
scattering technique (Malvern Zetasizer, ZEN 3600, Malvern 
Instruments, UK). The entrapment efficiency (EE%) was 
determined in triplicate using the total amount of drug added 
and the amount of drug in nanoparticles according to the 
following formula: 
EE%= (Amount of drug in nanoparticles)/(Total amount of 
drug)  ×100 
The amount of drug in NLCs was measured after extracting 
the drug from the particles by phase separation using PBS: 
octanol (1:3 v/v) where the NLCs were initially dissolved in 
octanol prior to the addition of PBS [23, 24]. The amount of 
drug in a known volume of PBS was then determined by 
HPLC.  
2.5. Ex vivo measurement of precorneal residence time 
A system based on the ex vivo method for evaluation of 
precorneal residence of topical ophthalmic formulations was 
used with some modifications [25]. It consisted of a 
perfusion chamber, two precision pumps to pump in/out the 
perfusion solution and a fluorescence microscope. Rat eyes 
were used as the biomembrane in this study. The cornea was 
removed immediately after euthanizing the animal and 
placed on a glass slide. The mucin solution (5 µL, 4% w/v) 
was added onto the surface of the cornea followed by 5 µL 
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of fluorescein containing NLCs. Subsequently, the perfusion 
chamber was attached to the cover slip and the pumps were 
turned on to allow the perfusion medium (PBS, pH 7.4) to 
flow over the corneal surface at a rate of 4 µl mL-1. 
Fluorescent images of the cornea were taken at 30 sec 
intervals for 60 min and the fluorescein intensity was 
measured with ImageJ software (National Institutes of 
Health, USA).  
2.6. In vitro drug release 
In vitro release studies were carried out using Franz-type 
diffusion chambers (Logan Instruments, USA) at 34 ± 1 oC 
under stirring at 100 rpm. A cellulose dialysis membrane 
with a molecular weight cut-off of 12,400 Dalton was used 
as diffusional barrier. Membranes were soaked in PBS 
overnight and washed with water before being mounted onto 
the diffusion cells. The receptor compartment was filled with 
freshly prepared PBS of pH 7.4. Samples were taken from 
the receptor chamber at predetermined time intervals and 
replaced with an equal volume of fresh buffer to maintain 
sink conditions. The amount of drug diffused was 
determined using HPLC [2].  
2.7. Ex vivo drug permeation through the cornea 
Experiments to determine drug permeation through the 
cornea were conducted using Franz-type diffusion chambers 
under the same condition as described above, except that 
bovine corneas were used instead of the cellulose membrane. 
Bovine eyes were collected from Auckland Meat Processors 
Limited (Auckland, New Zealand) immediately after 
slaughtering of the animal and corneas were excised 
carefully to avoid any damage. Corneas were then placed 
between the donor and receptor compartments.  
The apparent permeability coefficient was calculated using 
the following equation [26]: 
Papp = ΔQ/Δt*(3600)*A*C0 
where ΔQ/Δt is the permeation rate (μg h-1) obtained from 
the slope of the linear line of corneal penetration of ACV 
versus time, 3600 is the unit conversion from hrs to sec, A is 
the sample surface area (1.7 cm2) and C0 is the initial 
concentration of ACV in the carrier system (μg mL-1).  
2.8. MTT cell proliferation assay 
A MTT stock solution (5 mg mL-1) was prepared in RPMI-
1640 without phenol red, filtered through a 0.2 μm filter and 
stored at 2-8 °C. A MTT working solution was prepared by a 
1:10 dilution of the 5 mg mL-1 stock. Thereafter, cultured 
Vero cells were washed with warm RPMI-1640 without 
phenol red before incubating with MTT working solution at 
37 °C for 2 hrs. The converted dye was then solubilized with 
1 mL of acidic isopropanol (0.04 M HCl in absolute 
isopropanol), transferred into a 1.5 mL Eppendorf tube and 
centrifuged at 13,000 rpm for 2 min. The supernatant was 
transferred into a new Eppendorf tube. Absorbance of the 
converted dye was measured at 570 nm with background 
subtraction at 650 nm.  
2.9. Determination of the antiviral efficacy of ACV 
loaded NLCs 
Monkey kidney cells (CV-1) were used for the antiviral 
efficiency assay. Cell cultures were grown and maintained in 
DMEM supplemented with 10% v/v FBS and 1% w/v 
penicillin-streptomycin. HSV-1 was a hospital isolate 
amplified in human fetal fibroblasts that stained positive for 
a HSV-1 specific antibody. The virus titre was determined 
by a plaque reduction assay expressed as plaque forming 
units (pfu mL-1). Cells were infected by allowing them to 
absorb the virus for 2 hrs at 37 oC. The non-absorbed virus in 
solution was then removed and cells were washed with 
culture medium. A plaque assay was then performed to 
measure the number of infectious virus particles. Plaques 
were produced in a monolayer of CV-1 where a single virus 
infects a cell and the progeny produced infects the 
neighbouring cells.  
The antiviral efficacy of NLCs containing ACV was 
measured by a plaque reduction assay of HSV-1 replication 
in Vero cells. Concentrations of released drug necessary to 
reduce plaque formation by 50% (EC50) was measured and 
compared to an ACV solution. Briefly, cells were plated in 
six-well plates and incubated at 37 °C. When cells reached 
confluence, the medium was aspirated and a quantity of virus 
sufficient to yield 20 to 30 plaques per well was added. After 
removal of the inoculum (1 hr), cells were incubated in 
growth medium containing the NLCs at a range of 
concentrations. When plaques were formed, monolayers 
were stained with 1% w/v crystal violet in 20% v/v methanol 
and plaques were counted using a stereomicroscope. The 
EC50 was calculated using Prism software by comparing 
drug-treated with untreated cultures. 
2.10. Cellular uptake of fluorescein-loaded NLCs 
Primary human corneal epithelial cells (HCEC) were plated 
in a 24-well plate as a monolayer on round coverslips at a 
density of 4×104 cells/well at 37 oC in a 5% CO2 and 95% air 
atmosphere and incubated for 24 hrs to attach. Dulbecco 
modified Eagle’s medium (DMEM), supplemented with 
15% v/v heat inactivated fetal bovine serum (FBS), 10 ng 
mL−1 human epidermal growth factor (EGF), 5 μg mL−1 
insulin, 5 μg mL−1 human transferrin, 0.4 μg mL−1 
hydrocortisone, 2 mM L-glutamine and 100 U mL−1 
penicillin–100 μg mL-1 streptomycin was used as the culture 
medium. When the cells were at least 90% confluent, they 
were treated with fluorescein-loaded NLC dispersions in a 
supplement free culture medium. The concentration of lipid 
and fluorescein in the samples was maintained at 4.0 and 
0.01 mg mL-1 respectively. The control was incubated with 
the fluorescein solution (0.01 mg mL−1) in a supplement-free 
culture medium. 
At different time points (0, 2, 4 and 12 hrs) cells were 
washed three times with PBS (pH 7.4), cover slips were 
mounted on a glass slide and observed under a fluorescence 
microscope. Each treatment was performed in triplicate and 
at least three independent fields of each slide were 
photographed using a confocal laser scanning microscope 
(FV1000, Olympus, Germany). 
2.11. Cellular uptake of ACV-loaded NLCs 
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HCEC cells were grown as described above with 1 mL 
DMEM in each well before inoculation with 10 µL of the 
following test solutions: chitosan coated NLCs, uncoated 
NLCs and ACV suspension all containing 0.3% w/v of 
ACV. At specific time points (0.5, 1, 2 and 4 hrs), the 
medium was removed and cells were washed with PBS. A 
200 µL volume of trypsin was added to each well and the 
contents were centrifuged at 12,000 rpm for 10 min. 
Sedimented cells were re-suspended in 150 µL of PBS and 
freeze-thawed thrice to lyse the cell membranes. A volume 
of 100 µL of the cell suspension was diluted with 100 µL of 
PBS, vortexed for 5 min and centrifuged at 12,000 rpm for 
10 min. The resultant solution was subjected to HPLC to 
quantify the amount of ACV taken up by the cells. The 
protein content of the cells was measured using a Coomassie 
Blue staining protein assay kit. The uptake of the drug was 
calculated using the following equation: 
 
Drug uptake (μg mg-1 protein) = C/M 
 
Where C is the intracellular concentration of ACV and M is 
the unit weight (mg) of cellular protein. All experiments 
were carried out in triplicate.  
2.12. In vivo evaluation of ACV loaded NLCs 
New Zealand albino rabbits (3-4 kg) were used in 
accordance with the University of Auckland guidelines for 
the use of laboratory animals in research and were checked 
for any signs of ocular damage. Rabbits were confined in 
standard rabbit cages in a light and temperature controlled 
room and were free to move with no restriction of food, 
water or eye movements. Animals were divided into five 
groups: the first group received the commercially available 
3% w/v ACV ophthalmic ointment, the second group 
received a 0.3% w/v ACV ophthalmic ointment diluted in 
petroleum jelly, the third group received 0.3% w/v ACV 
loaded NLCs in the form of an ocular suspension and the 
fourth and fifth group received a 3% w/v and 0.3% w/v ACV 
suspension in buffer respectively. Therefore, 36 animals 
were used in each study group from which six animals were 
humanely killed at each time point by injection of an 
overdose of sodium pentoparbitone (300 mg mL-1) into the 
marginal ear vein.  
The formulation (20 µL) was instilled in the cul-de-sac of the 
eye by pulling the lower lid forward. After instillation, the 
lower lid was lifted back and forth to allow mixing of the 
formulations with the lacrimal fluid [21]. At specific time 
intervals (0.5, 1, 2, 4, 6 and 24 hrs) six animals were 
euthanized and aqueous humour samples were obtained by a 
syringe using a 26G ½ needle. An appropriate amount of the 
internal standard, guanosine, was added to each vial and 150 
µL of collected aqueous humour samples were treated with 
150 µL of 2% w/v zinc sulphate. The mixture was vortexed 
for 1 min and centrifuged at 6,000 rpm for 20 min [9, 27, 
28]. The clear supernatant was filtered through a 0.22 µm 
filter and 50 µL were injected into the HPLC for analysis 
with guanosine used as HPLC internal standard. 
2.12. Statistical analysis 
Student t-test was used to analyse data obtained from two 
populations at the 0.05 level of significance while one-way 
analysis of variance (ANOVA) was used for analysis of 
more than two populations by GraphPad software.  
3. RESULTS AND DISCUSSIONS  
3.1. Effects of chitosan coating on NLC characteristics 
Chitosan is expected to cover the surface of the NLCs in a 
saturable process with the negatively charged lipid 
Compritol providing sufficient negative charge to attract the 
positively charged chitosan molecules. The finished product 
can be in the form of a freshly formed suspension for 
immediate application or a freeze-dried redispersible powder 
providing longer shelf life [29, 30].  
3.2. Freeze-dried formulation 
Table 1 lists the effect of increasing chitosan concentrations 
on particle size and zeta potential of freeze dried NLCs, with 
coating resulting in a significant increase in the particle size 
(P<0.05). It is apparent that particles coated with the lowest 
concentration of chitosan (0.1% w/v) had the largest size 
compared to uncoated particles. This may be due to a very 
low zeta potential (3.86 ± 0.73) leading to particle-particle 
attraction and aggregation. Generally, a value close to ±30 
mV is considered optimal to stabilize a nanosuspension 
where particle-particle repulsion forces inhibit aggregation 
of the nanoparticles [31]. Increasing the concentration of 
chitosan resulted in an increase in the zeta potential and a 
decrease in particle size, although NLCs coated with 0.25 
and 0.5% w/v chitosan solution remained in the micro size 
range. Coating of freeze-dried NLCs resulted in 
agglomeration and the formation of microparticles similar to 
what was reported by Dharmala [32]. Therefore, to obtain 
chitosan coated particles in the nano-size range freshly 
prepared nano-suspensions were used.   
 
Table 1 Physiochemical properties of freeze-dried NLCs 
coated with different LCH concentrations (n=3, mean ± SD). 
Chitosan (% w/v) Zeta potential 
(mV) 
Particle size (nm) 
0 -32.16 ± 3.39 801.33 ± 84.05 
0.1  3.86 ± 0.73 4690.00 ± 86.86 
0.25 30.26 ± 1.40 4439.00 ± 252.93 
0.5 45.96 ± 1.70 3084.00 ± 725.53 
3.3. Freshly prepared formulation 
Table 2 lists the physiochemical properties of freshly 
prepared coated and uncoated NLCs. Plain NLCs were 
323.33 ± 14.6 nm in diameter with the diameter increasing as 
a result of surface coating with chitosan. At relatively low 
concentrations of chitosan (0.1% w/v), the particle size 
increased significantly (P<0.05) as the induced positive 
charges were not sufficient to stabilize the NLC suspension 
[33]. In other words, due to the low surface charge, particle-
particle attraction forces were strong and resulted in 
aggregation of the nanoparticles.  
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However, as the concentration of chitosan increased, the 
positive surface charges also increased resulting in particle-
particle repulsion. This led to the formation of a stable 
suspension in which the nanoparticles did not aggregate and 
therefore the mean particle size was increased only slightly 
compared to uncoated NLCs. The zeta potential of the NLCs 
was converted from -25.5 ± 1.65 to +28.1 ± 0.72 mV 
confirming successful coating. Statistical analysis showed 
that the change in particle size was significant for all samples 
(P<0.05). 
Table 2 also lists the ACV entrapment efficiency of the 
coated formulations. When compared to the uncoated 
particles, the slight decrease in the EE% was insignificant 
after coating (P>0.05). This means that the coating did not 
interfere with the encapsulated drug, although some of the 
drug adsorbed onto the surface of the nanoparticles might 
have been lost in the aqueous solution of chitosan leading to 
the slight decrease in EE% [33]. 
 
Table 2 Physicochemical properties of fresh NLCs coated 










0 323.33 ± 14.60 -25.50 ± 1.65 90.54 ± 6.74 
0.1 529.90 ± 86.86  5.03 ± 1.01 85.63 ± 5.14 
0.25 444.73 ± 21.16 17.56 ± 0.85 86.32 ± 4.51 
0.5 457.30 ± 44.38 28.10 ± 0.72 84.76 ± 1.23 
1 467.46 ± 56.25 28.20 ± 0.57 87.94 ± 1.93 
3.4. Corneal perfusion study and ex vivo corneal 
residence time 
Figure 1 shows the fluorescent images obtained at different 
time points when various NLCs loaded with fluorescein were 
applied onto the surface of the rat corneas illustrating a 
typical fluorescein intensity decay profile for each 
formulation. One of the advantages of NLCs is that they are 
capable of entrapping both hydrophilic and lipophilic 
molecules. This allows the hydrophilic sodium fluorescein to 
be entrapped within the NLCs internal spaces. Images were 
taken from the center of the rat excised cornea placed in the 
perfusion chamber. The decrease in fluorescence intensity 
over time predicts the precorneal residence of the 
formulations [25].  
A 0.01 mg mL-1 solution of fluorescein sodium used as 
control was completely flushed away from the cornea after 
only 15 min with the image being completely dark at 30 min. 
NLCs, however, retained the dye on the surface of the cornea 
for an extended period of time. As the concentration of 
chitosan increased from 0.1 to 0.5% w/v the corneal 
residence time also increased significantly (P<0.05) due to 
interactions of the positively charged particles with the 
negative charges on mucin and epithelial cells. NLCs coated 
with 0.5% w/v chitosan solution retained the fluorescent dye 
even after 45 min of exposure as shown in Figure 1.  
 
Figure 1 Precorneal residence of the fluorescein loaded 
formulations over time. 
Figure 2 shows the fluorescein decay as a function of time. 
To quantitatively analyze the data obtained from the corneal 
perfusion study, the fluorescence intensity of each 
concurrent image taken at 30 sec intervals was integrated 
using ImageJ software (National Institutes of Health, USA). 
It is evident from the obtained data that coating of NLCs 
with an increasing chitosan concentration resulted in 
increased bioadhesion and extended corneal residence time. 
The bioadhesive nature of chitosan, its cationic charge and 
increased viscosity of the system hereby contributed to the 
increased surface adhesion of the nanoparticles. Other 
studies have also shown that the addition of a bioadhesive 
coating can significantly increase the precorneal retention 
time of NLCs [34]. In a study by Shen [34], a dramatic 
increase in periocular retention time of NLCs coated with a 
thiolated non-ionic surfactant, cysteine-polyethylene glycol 
stearate (Cys-PEG-SA) was demonstrated for up to 6 hrs.  
 
 
Figure 2 Precorneal residence time of fluorescein loaded 
formulations as a function of time measured by ImageJ 
software. 
3.5. In vitro drug release 
The in vitro drug release profiles of different formulations 
are shown in Figure 3. The ACV suspension in PBS pH 7.4 
freely passed through the artificial membrane proving that 
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drug diffusion through the artificial barrier was not the rate 
limiting factor. The freshly prepared NLCs had a slower 
drug release profile compared to the freeze-dried particles. 
However, after coating NLCs with chitosan, there was a 25% 
reduction in the drug release rate. The chitosan coat is 
insoluble at physiological pH and retains its integrity and 
therefore restrains drug release [17]. Although water 
insoluble, the chitosan coating layer absorbs water and 
swells which provides hydrated channels for slow release of 
the drug over time [35]. Figure 3 reveals that increasing the 
concentration of chitosan did not influence the release 
parameters significantly (P<0.05).  
 
 
Figure 3 In vitro release profiles of ACV suspension, 
uncoated NLCs and NLCs coated with 0.1 , 0.25 and 0.5 % 
w/v chitosan  (n=3, mean ± SD).  
3.6. Ex vivo corneal penetration studies 
Bovine eyes were used in ex vivo corneal permeation studies 
because they are easily obtained and the diameter allows a 
proper fit over Franz cells [36, 37]. Figure 4 displays the ex 
vivo ACV corneal penetration profiles for the different 
formulations.  
 
Figure 4 Corneal penetration profile of the ACV suspension, 
uncoated NLCs and NLCs coated with 0.1, 0.25 and 0.5% 
w/v chitosan (n=3, mean ± SD). 
The ACV control suspension had the slowest penetration rate 
but inclusion of ACV into NLCs slightly improved its 
corneal penetration due to their lipophilic nature [2]. There 
was a slight improvement in Papp of ACV from 8.78 ± 0.01 to 
9.12 ± 1.16 which was insignificant (P>0.05). Coating of 
NLCs with chitosan and increasing its concentration also 
resulted in an insignificant increase in the drug permeation 
through excised bovine corneas (P>0.05). However, NLCs 
coated with 0.5% w/v chitosan had the maximum penetration 
through the cornea (Papp=14.74 ± 5.03) and there was more 
than a 1.5 fold increase in permeability when compared to 
the ACV suspension although the difference was statistically 
insignificant (P>0.05). In addition to its bioadhesive nature, 
chitosan is also a cell membrane penetration enhancer [38], 
which has been attributed to the modulation of the tight 
junction barriers between corneal epithelial cells [39] and 
also intracellular routes [17, 40]. In a recent study, NLCs 
coated with chitosan oligosaccharides also improved corneal 
penetration of a model drug, flurbiprofen, by 2.4 folds 
compared to uncoated NLCs supposedly due to opening of 
corneal epithelial tight junctions by chitosan [41].  There is 
no established data for the exact mechanism of chitosan 
mediated increased corneal epithelial permeation although it 
has been illustrated in Caco-2 cells that chitosan causes a 
reversible, time and dose dependent decrease in trans-
epithelial electrical resistance by affecting paracellular and 
intracellular pathways of epithelial cells in a reversible 
manner without causing cellular toxicity [40].  
3.7. MTT cell proliferation assay 
The MTT cell proliferation assay on Vero cells showed that 
the cytoxicity increased with an increase in the concentration 
of NLCs used. The LD50 of ACV loaded NLCs was 1086 µg 
mL-1  which closely resembles values reported for other lipid 
based nanocarriers [42]. The LD50 of the empty NLCs was 
1015 µg mL-1 which was not significantly different to that 
of the drug loaded NLCs (P>0.05). This shows that the drug 
itself does not impose any toxic effects on the cells. The 
LD50 of the chitosan coated NLCs was 1047 µg mL-1 which 
was not significantly different to the values obtained for the 
uncoated nanoparticles (P>0.05).  
3.8. Antiviral efficacy of NLCs 
The antiviral efficacy of the NLCs was determined after 24 
and 48 hrs of treatment on a monolayer of Vero cells 
infected with the purified HSV-1 viral stock. The ACV 
containing NLCs exhibited a concentration dependent plaque 
reduction profile. Figure 5 shows the dose response curve of 
the ACV suspension and the ACV containing NLCs after 24 
and 48 hrs of treatment respectively. The effective 
concentration to achieve 50% inhibition of viral replication 
(IC50) was calculated by plotting the Log concentration 
versus plaque reduction graphs. Encapsulation of ACV in 
NLCs resulted in a 3.5-fold reduction in the required dose to 
achieve 50% reduction in viral plaques. The IC50 of ACV in 
suspension versus ACV in NLCs was 0.018 ± 0.010 versus 
0.063 ± 0.030 after 24 hrs and 0.017 ±0.020 versus 0.061 ± 
0.010 after 48 hrs of treatment. Based on these results, the 
antiviral efficacy of ACV was increased when formulated as 
NLCs.  
NLCs are thought to enhance the antiviral efficiency of ACV 
by enhancing drug penetration into infected cells as well as 
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prolonging the exposure of the infected cells to the antiviral 
agent through their sustained release characteristics. 
Moreover, the membrane perturbation caused by the virus 
makes the infected cells a natural target for particulate drug 
delivery systems [43, 44]. The enhanced antiviral property of 
ACV in NLCs could be due to two different mechanisms: 1) 
The sustained drug release properties of NLCs which would 
have increased the exposure time of the infected cells to the 
drug resulting in a more efficient treatment and 2) the cell 
internalizing properties of NLCs as the drug in solution 
would not be taken up by cells in sufficient amounts to 
eradicate the virus within the cells. 
 
 
Figure 5 Antiviral efficacy of ACV in solution (ACV) and 
ACV encapsulated NLCs (NP) after (A) 24 hrs and (B) 48 
hrs treatment. 
3.9. Cellular uptake of NLCs 
Figure 6 shows the fluorescein uptake into corneal epithelial 
cells after being treated with the control fluorescein solution, 
fluorescein loaded NLCs and fluorescein loaded chitosan 
coated NLCs.  
 
 
Figure 6 Fluorescein uptake of (A) control fluorescein 
solution, (B) NLCs and (C) NLCs coated with 0.5% w/v 
chitosan after 2, 4 and 12 hrs. 
It is evident that cells were confluent and remained 
impermeable to fluorescein even after 12 hrs of incubation. 
When cells were treated with NLCs the particles seemed to 
adhere to the exterior surface of the cells without 
internalization (Figure 6B). The fluorescein intensity on the 
cells increased with longer incubation times as NLCs are 
expected to form a film on the surface of the corneal 
epithelial cells. A closer look at the fluorescein images 
displayed in Figure 6C revealed that they differ considerably 
from the images obtained after treating the cells with the 
control and plain NLCs. Decisively, addition of chitosan to 
the formulations allowed the nanoparticles to be internalized 
with fluorescein present in the cytoplasm of the epithelial 
cells which seemed to intensify over time. This was expected 
as chitosan is known for its corneal penetration enhancing 
properties [38, 45-47].  
 
Figure 7 shows the intracellular ACV concentrations after 
exposure to the ACV suspension and ACV loaded NLCs 
(coated and uncoated). The cellular uptake of ACV in 
chitosan coated NLCs was higher than that of uncoated 
NLCs and ACV in suspension. The chitosan coated system 
had the highest drug cellular uptake due to the cell 
penetration enhancing properties of chitosan. It should be 
noted that the results obtained here are only a relative 
measure of ACV cell uptake since the Coomassie Brilliant 
Blue test used to quantify the total amount of cellular 
proteins is only semi-quantitative. 
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Figure 7 Cellular uptake concentration profile of ACV in 
solution (ACV), uncoated NLCs (NLCs) and NLCs coated 
with 0.5% chitosan (NLCs-LCH). 
3.10. In vivo corneal permeation 
The only marketed ophthalmic preparation of ACV is in the 
form of a 3% w/v ointment (ZoviraxTM) which is due to the 
low solubility of the drug in aqueous medium. Novel drug 
delivery systems promise to increase the ocular 
bioavailability of drugs and by doing so would decrease the 
required loading dose [48, 49]. The chitosan coated NLCs 
system under investigation contained 0.3% w/v of ACV 
which is ten times lower than the marketed ophthalmic 
ointment.  
 
Table 3 Aqueous humour pharmacokinetic parameters  
of the formulations. 
 
 
Therefore, to establish a control formulation of similar 
concentration, ZoviraxTM ointment was diluted with 
petroleum jelly to obtain a 0.3% w/v ACV ointment. Figure 
8 shows the ACV concentrations in the aqueous humour 
with the corresponding pharmacokinetic data reported in 
Table 3. The relative AUC for ACV in NLCs increased 4.17 
times when compared to the ointment and 6.93 times when 
compared to the eye drop. The Cmax for ACV in NLCs 
increased by 3 and 4.5 times respectively when compared to 
the ointment and eye drop controls. 
 
Both ophthalmic ointment and NLCs reached the Cmax 1 hr 
after topical administration (Tmax=60 min); however, the eye 
drop control reached Cmax 30 min post administration. This is 
due to the immediate availability of the drug from solution 
for absorption and penetration across the cornea [50]. 
 
 
Figure 8 Drug concentration profile of NLCs coated with 
0.5% w/v chitosan (NLCs-LCH 0.5%w/v), a 0.3% w/v ACV 
eye drop and a 0.3% w/v ophthalmic ointment in the aqueous 
humour. 
Figure 9 shows the aqueous humour ACV profiles for the 
chitosan coated NLCs when compared to the 3% w/v 
ophthalmic ointment and the 3% w/v ACV suspension. 
Although the commercial ointment had ten times more ACV 
loaded, the AUC for both NLCs and ointment remained 
similar with the difference being insignificant (P>0.05) 








AUC (min µg mL-1 ) 
 
Relative AUC 
NLC-LCH 1.56 ± 0.43 60 275.9 ± 70.49 4.17 
3% w/v Ointment 1.80 ± 0.96 60 252.7 ± 84.42 3.82 
0.3% w/v Ointment 0.52 ± 0.10 60 66.07 ± 66.06 1.00 
3% w/v ACV 
suspension 
0.42 ± 0.23 30 44.46 ± 32.10 0.67 
0.3% w/v Eye drop 0.34 ± 0.11 30 39.78 ± 29.62 0.60 
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illustrates the low efficacy of the ophthalmic ointment for 
this particular treatment [51]. By increasing the 
concentration of the ACV control suspension from 0.3 to 3% 
w/v, the ocular bioavailability of ACV did not increase 
significantly (P>0.05) and the time to reach the maximum 
concentration (Tmax) remained the same. This illustrates that 
the drug reached super saturated solubility levels and 
addition of an excess of ACV in the form of a suspension 
offered no obvious benefit. The Tmax for the NLCs was very 
similar to what has been reported for ACV loaded liposomes  
[21]. This shows that the positively charged chitosan coated 
NLCs had a controlled and slow penetration through the 
cornea [21]. Also, NLCs had much higher aqueous humour 
concentrations when compare to the ointment and eye drop 
formulations of the matching concentration confirming that 
the NLCs coated with chitosan enhanced the penetration of 
ACV through the cornea.   
 
Figure 9 ACV concentration profiles in aqueous humour 
after application NLCs coated with 0.5% w/v chitosan 
(NLCs-LCH 0.5% w/v), 3% w/v ACV aqueous suspension 
and 3% w/v ACV ophthalmic ointment. 
Most nano- and microencapsulated systems are capable of 
enhancing the aqueous humour permeation profile of ACV 
when compared to the control solution of matching 
concentration [21, 27, 28, 51]. Only one study included the 
commercial ophthalmic ointment as a control [51]. It is vital 
to maintain a therapeutic concentration of ACV throughout 
the ocular tissues to eradicate any sign of a deeper ocular 
infection, to inhibit viral latency development and to avoid 
vision loss associated with secondary herpes infections [52]. 
This study has shown that NLCs can deliver increased 
amounts of drug in cornea, aqueous humour and vitreous 
humour over an extended period of time in comparison to the 
commercial ointment.   
CONCLUSION 
 A novel lipid based nanoparticulate drug delivery 
system (NLCs) coated with a bioadhesive and biodegradable 
polymer, chitosan, was designed and developed for ocular 
delivery of the antiviral drug ACV. In summary, the 
developed ocular drug delivery system was able to: 
 
- enhance the antiviral efficacy of the drug, 
- illustrate no toxicity and thus suitability for ocular 
drug delivery, 
- show increased drug cellular uptake, 
- demonstrate a controlled drug release profile in 
vitro, 
- increase the ex vivo penetration of the drug through 
the cornea, 
- exhibit a prolonged precorneal  residence time and 
- achieve higher ocular drug bioavailability in 
comparison to the commercially available 
ophthalmic ointment. 
It is therefore reasonable to state that pharmaceutical 
nanotechnology has the potential to optimize topical ocular 
drug delivery of poorly soluble drugs. The commercial 
potential and ease of the scale up manufacturing process 
support the recognized pharmaceutical advantage of lipid 
nanoparticles over conventional ophthalmic dosage forms. 
This nanoparticulate formulation is a versatile delivery 
system capable of encapsulating both hydrophilic and 
lipophilic drugs. Thus, it could serve as a delivery platform 
for many other drugs including anti-inflammatory agents, 
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